OncoMatch/Clinical Trials/NCT06869278
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Is NCT06869278 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LCAR-AIO T cells for multiple sclerosis (ms).
Treatment: LCAR-AIO T cells — This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: AQP4 IgG positive
AQP-4 IgG (NMOSD)...should be positive by CBA (Cell based transfection immunofluorescence assay)
Required: MOG IgG positive
MOG-IgG (MOGAD) should be positive by CBA (Cell based transfection immunofluorescence assay)
Required: CHRNA1 AChR-IgG positive
AChR-IgG...should be positive
Required: MUSK MuSK-IgG positive
MuSK-IgG should be positive
Prior therapy
Must have received:
Fulfill relapsed/refractory MS conditions
Must have received:
Fulfill relapsed/refractory NMOSD/MOGAD conditions
Lab requirements
Blood counts
Clinical laboratory values meet criteria at screening visit
Kidney function
Adequate organ function at screening
Liver function
Adequate organ function at screening
Adequate organ function at screening. Clinical laboratory values meet criteria at screening visit.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify